{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:21:30Z","timestamp":1782800490736,"version":"3.54.5"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNCI J Natl Cancer Inst"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1093\/jnci\/djw248","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T11:06:01Z","timestamp":1476270361000},"page":"djw248","source":"Crossref","is-referenced-by-count":28,"title":["T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment"],"prefix":"10.1093","volume":"109","author":[{"given":"Carla","family":"Casulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,12,31]]},"reference":[{"issue":"11","key":"2016123117301573000_109.2.djw248.1","first-page":"3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"The Non-Hodgkin's Lymphoma Classification Project. Blood"},{"key":"2016123117301573000_109.2.djw248.2","unstructured":"Swerdlow SHN Jaffe E Pileri S , . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008."},{"key":"2016123117301573000_109.2.djw248.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"2016123117301573000_109.2.djw248.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"2016123117301573000_109.2.djw248.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"2016123117301573000_109.2.djw248.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"2016123117301573000_109.2.djw248.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"2016123117301573000_109.2.djw248.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"2016123117301573000_109.2.djw248.9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20999"},{"key":"2016123117301573000_109.2.djw248.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"2016123117301573000_109.2.djw248.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"2016123117301573000_109.2.djw248.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"2016123117301573000_109.2.djw248.13","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.816700"},{"key":"2016123117301573000_109.2.djw248.14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27733"},{"key":"2016123117301573000_109.2.djw248.15","doi-asserted-by":"crossref","unstructured":"Swerdlow SH Campo E Pileri SA . The 2016 Revision of the World Health Organization (WHO) Classification of Lymphoid Neoplasms. Lyon, France: International Agency for Research on Cancer; 2016.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2016123117301573000_109.2.djw248.16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.261"},{"key":"2016123117301573000_109.2.djw248.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3719"},{"key":"2016123117301573000_109.2.djw248.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578575"},{"key":"2016123117301573000_109.2.djw248.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544809"},{"key":"2016123117301573000_109.2.djw248.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359"},{"key":"2016123117301573000_109.2.djw248.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391748"},{"key":"2016123117301573000_109.2.djw248.22","doi-asserted-by":"publisher","DOI":"10.1038\/nature08617"},{"key":"2016123117301573000_109.2.djw248.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509"},{"key":"2016123117301573000_109.2.djw248.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408542"},{"key":"2016123117301573000_109.2.djw248.25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26833"},{"key":"2016123117301573000_109.2.djw248.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112"},{"key":"2016123117301573000_109.2.djw248.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.006"},{"key":"2016123117301573000_109.2.djw248.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303305"},{"key":"2016123117301573000_109.2.djw248.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091"},{"key":"2016123117301573000_109.2.djw248.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-419937"},{"key":"2016123117301573000_109.2.djw248.31","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001683615"},{"key":"2016123117301573000_109.2.djw248.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.8793"},{"key":"2016123117301573000_109.2.djw248.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"2016123117301573000_109.2.djw248.34","doi-asserted-by":"crossref","unstructured":"O'Connor OA Ozcan M Jacobsen E , . First multicenter, randomized phase\u00a03 study in patients (Pts) with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL): Alisertib (MLN8237) versus investigator's choice (Lumiere trial; NCT01482962). Paper presented at the 57th Meeting of the American Society for Hematology; December 2015; Orlando, FL.","DOI":"10.1182\/blood.V126.23.341.341"},{"key":"2016123117301573000_109.2.djw248.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"2016123117301573000_109.2.djw248.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.08.001"},{"issue":"16","key":"2016123117301573000_109.2.djw248.37","first-page":"5494","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin","volume":"10","author":"Ishida","year":"2004","journal-title":"Cancer Res."},{"key":"2016123117301573000_109.2.djw248.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"2016123117301573000_109.2.djw248.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"2016123117301573000_109.2.djw248.40","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"2016123117301573000_109.2.djw248.41","doi-asserted-by":"crossref","unstructured":"Mehta-Shah N Lunning MA Ruan J . A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma. Paper presented at the 13th International Conference on Malignant Lymphoma; June 2015; Lugano, Switzerland.","DOI":"10.1200\/jco.2015.33.15_suppl.8521"},{"key":"2016123117301573000_109.2.djw248.42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2249"},{"key":"2016123117301573000_109.2.djw248.43","doi-asserted-by":"crossref","unstructured":"Fanale MA Hagemeister FB Fayad L , . A phase I trial of alisertib plus romidepsin for relapsed\/refractory aggressive B- and T-cell lymphomas. Paper presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.1744.1744"},{"key":"2016123117301573000_109.2.djw248.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969"},{"key":"2016123117301573000_109.2.djw248.45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"2016123117301573000_109.2.djw248.46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434"},{"key":"2016123117301573000_109.2.djw248.47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"2016123117301573000_109.2.djw248.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"2016123117301573000_109.2.djw248.49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"2016123117301573000_109.2.djw248.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"2016123117301573000_109.2.djw248.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1150799"},{"key":"2016123117301573000_109.2.djw248.52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc839"},{"key":"2016123117301573000_109.2.djw248.53","doi-asserted-by":"crossref","unstructured":"Horwitz S Porcu P Flinn I , . Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma. Paper presented at the 56th Meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.803.803"},{"key":"2016123117301573000_109.2.djw248.54","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2873"},{"key":"2016123117301573000_109.2.djw248.55","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.347"},{"key":"2016123117301573000_109.2.djw248.56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7025"},{"key":"2016123117301573000_109.2.djw248.57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0028"},{"key":"2016123117301573000_109.2.djw248.58","doi-asserted-by":"crossref","unstructured":"Fleischmann R Kremer J Tanaka Y . Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: Review of key phase II studies. Int J Rheum Dis. 2016; in press.","DOI":"10.1111\/1756-185X.12901"}],"container-title":["Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/109\/2\/djw248\/17497440\/djw248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T05:12:52Z","timestamp":1657429972000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djw248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,31]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,12,31]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1093\/jnci\/djw248"],"URL":"https:\/\/doi.org\/10.1093\/jnci\/djw248","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,31]]}}}